The number of treatment options continues to increase in the T1D space. Existing agents fail to provide sustained and intrinsic control of T1D, and none address the autoimmune component of T1D’s etiology. The emphasis has shifted on the types of therapies in development for T1D, with a significant interest in immune modulation and cell-based therapies. The launch of biosimilar insulins is creating pricing pressure on branded originators in the major markets and giving payers greater leverage to negotiate price.
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.